Related Experiment Video

Updated: Aug 6, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER

Jure Murgić1, Ana Fröbe1,2, Amarnath Challapalli3

  • 1Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.

Acta Clinica Croatica
|March 20, 2023
PubMed

Insights

Novel androgen receptor targeted agents (ARTAs) are transforming localized high-risk prostate cancer treatment. This review explores current evidence and biomarker strategies for personalized therapy in this aggressive disease.

Area of Science:

  • Oncology
  • Urology

Background:

  • Anti-androgen therapy is a cornerstone for prostate cancer, both localized and metastatic.
  • Newer androgen receptor targeted agents (ARTAs) have significantly improved outcomes in advanced prostate cancer.
  • The integration of novel ARTAs into localized prostate cancer treatment, particularly high-risk disease, is a rapidly evolving area.

Purpose of the Study:

  • To review the current clinical evidence for novel ARTAs in localized high-risk prostate cancer.
  • To discuss the evolving role of these agents within a multidisciplinary treatment approach.
  • To highlight recent advancements in biomarker-driven strategies for personalized treatment.

Main Methods:

  • Narrative review of existing clinical studies and literature.
  • Analysis of data on novel androgen receptor targeted agents.
  • Examination of biomarker research in prostate cancer treatment individualization.

Main Results:

  • Novel ARTAs show promise in improving outcomes for localized high-risk prostate cancer.
  • Multidisciplinary treatment combined with systemic therapies enhances patient results.
  • Biomarker-driven strategies are crucial for tailoring treatment to individual patients.

Conclusions:

  • Novel ARTAs represent a significant advancement in the management of localized high-risk prostate cancer.
  • Personalized medicine approaches, guided by biomarkers, are key to optimizing treatment efficacy.
  • The integration of novel ARTAs into multidisciplinary care paradigms is redefining treatment standards.
Keywords:
Radiotherapy (RT)abirateroneandrogen deprivation therapy (ADT)androgen receptorandrogen receptor targeted agents (ARTAs)enzalutamideprostate cancer

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.9K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
904
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
236
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
948